Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
[18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot studyInga Buchmann, Bernd Neumaier, Mathias Schreckenberger, et al.
FEBS Letters|January 28, 2012
Is the chromanol head group of vitamin E nature's final truth on chain-breaking antioxidants?Maike J Ohlow, Matthias Granold, Mathias Schreckenberger, et al.
Nuklearmedizin. Nuclear Medicine|May 14, 2020
Improving treatment outcomes for Graves' disease patients with inactive forms of Graves' orbitopathy through an increased dose of radioiodine therapyJanika Gosmann, Diana Willms, Eberhard Bell, et al.
Pharmaceutical Research|November 30, 2016
Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical NeuroprotectionMaike J Ohlow, Selina Sohre, Matthias Granold, et al.
Archives of Surgery (Chicago, Ill. : 1960)|October 20, 2004
Prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinomaWerner Kneist, Mathias Schreckenberger, Peter Bartenstein, et al.
Molecules (Basel, Switzerland)|November 13, 2021
Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational ApproachHanane Lahnif, Tilmann Grus, Stefanie Pektor, et al.
World Journal of Surgery|August 15, 2003
Positron emission tomography for staging esophageal cancer: does it lead to a different therapeutic approach?Werner Kneist, Mathias Schreckenberger, Peter Bartenstein, et al.
Epilepsia|April 14, 2010
Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsyChristian Landvogt, Hans-Georg Buchholz, Viviane Bernedo, et al.
Clinical Nuclear Medicine|August 18, 2012
One single-time-point kidney uptake from OctreoScan correlates with number of desintegrations measured over 72 hours and calculated for the 6.7 hours half-life nuclide (177)LuMatthias Miederer, Helmut Reber, Andreas Helisch, et al.
Thyroid : Official Journal of the American Thyroid Association|November 13, 2003
Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institutionWaltraud Eichhorn, Harry Tabler, Rainer Lippold, et al.
Pageof 13